Home Beauty Health Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

on January 06, 2023
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate submitted by /u/Philip19967
[link] [comments]


from Health https://ift.tt/eV3o6j0
,
Share To:

Unknown

View Profile

Post A Comment:

0 comments so far,add yours

Subscribe to: Post Comments (Atom)